NCT01420952 is a Phase 1 clinical trial of [11C]LY2428703 in Dosimetry, sponsored by National Institute of Mental Health (NIMH).

Who is sponsoring NCT01420952?

NCT01420952 is sponsored by National Institute of Mental Health (NIMH).

What drugs are being tested in NCT01420952?

Interventions in NCT01420952: [11C]LY2428703.

What condition does NCT01420952 study?

NCT01420952 studies Dosimetry, Pharmacokinetics.

Is NCT01420952 still recruiting?

NCT01420952 is currently terminated. Last updated 16 December 2019.

Last reviewed 2019-12-16 · How we verify

NCT01420952

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Imaging of Brain Receptors Using (11C)mGlu1

Terminated Phase 1 Last updated 16 December 2019

What this trial tests

Phase 1 trial testing [11C]LY2428703 in Dosimetry in 3 participants. Terminated before completion.

Timeline

29 July 2011

Primary endpoint
27 November 2012

27 November 2012

Quick facts

Lead sponsor	National Institute of Mental Health (NIMH)
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	3
Start date	29 July 2011
Primary completion	27 November 2012
Estimated completion	27 November 2012
Sites	1 location across United States

Drugs / interventions tested

[11C]LY2428703 — full drug profile →

Conditions studied

Dosimetry — all drugs for Dosimetry →
Pharmacokinetics — all drugs for Pharmacokinetics →

Sponsor

National Institute of Mental Health (NIMH)

Who can join

Adults 18 to 50, any sex, with Dosimetry or Pharmacokinetics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: \- (11C)mGlu1 is a new drug that helps to show where a protein, mGluR1, is found in the brain. The drug contains a small amount of radioactivity that can be detected by imaging studies like positron emission tomography (PET) scans. By looking at the mGluR1 receptors, researchers hope to better understand how they are involved in general health, brain disorders, and addiction. Objectives: * To test how (11C)mGlu1 is distributed in the brain and body. * To measure how mGluR1 receptors display (11C)mGlu1 during imaging studies. Eligibility: \- Healthy volunteers between 18 and 50 years of age. Design: * Participants will be screened with a medical history, physical exam, and blood and urine tests. This study requires four visits to the NIH Clinical Center. * Participants will have an initial evaluation, a magnetic resonance imaging (MRI) scan, a PET scan, and a final blood sample after the PET scan, all at different visits. * The MRI and PET scans will focus on the brain. Participants will receive (11C)mGlu1, and have scans to see how it shows up in the brain. * Some participants will have whole body imaging studies to see how (11C)mGlu1 shows up in the body.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other National Institute of Mental Health (NIMH) trials

Trials by the same sponsor.

NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT05652465 — Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder · Phase 2 · suspended
NCT07027839 — Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B) · Phase 1 · recruiting
NCT06920628 — PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 In · Phase 1 · recruiting
NCT06874205 — Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01420952 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Mental Health (NIMH)
Last refreshed: 16 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01420952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing